Navigation Links
Cancer drug effectively treats transplant rejections
Date:12/26/2008

CINCINNATIUniversity of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.

Results of the study are published in the Dec. 27, 2008, edition of the journal Transplantation.

Steve Woodle, MD, and colleagues found that a cancer drugbortezomibused to treat multiple myeloma, or cancer of the plasma cells, is effective in treating rejection episodes caused by antibodies that target transplanted kidneys and reversing rejection episodes that did not respond to standard therapies.

B-lymphocytes, or B cells, play a large role in the humoral immune response by making immune proteins that attack transplanted organs.

"We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory," says Woodle, lead author of the study and chief of transplant surgery at UC. "Moreover, it worked well in models of autoimmune diseases."

T-lymphocytes, or T cells, are white blood cells that were commonly thought to cause the rejection of transplanted organs.

Woodle and his team began searching for agents that targeted plasma cells in 2005.

"It has become clear that plasma cells and the antibodies they produce play a bigger role in rejection than previously thought, and the development of therapies targeting these cells has lagged," he says. "We realized that current therapies don't target the plasma cells which may produce the antibody, in general."

Researchers administered this drug to six kidney transplant recipients with treatment-resistant organ rejection, evaluating and recording their responses to the treatment.

In each case, treatment with the drug provided prompt rejection reversal, prolonged reductions in antibody levels and improved organ function with suppression of recurrent rejection for at least five months.

Jason Everly, a board-certified oncology pharmacist in the division of transplant surgery at UC and co-author of the study, says the toxicities associated with this drug were predictable and manageable and were much less than those associated with other anti-cancer agents.

"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," he adds. "We hope it will be a viable therapeutic treatment option in this patient group."

Woodle says although this data is promising, it is difficult to overestimate the implications of this drug.

"We have an immunosuppressive agent that for the first time can target antibody-producing plasma cells with an efficacy similar to drugs that target T cells," he says. "This has significant implications for transplantation and auto immune disease."

UC researchers are currently conducting four industry-supported clinical trials to expand these findings.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. A new light on tumor immunotherapy for gastric cancer
2. Cancer Medicine Advances on Many Fronts
3. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
4. E. coli engineered to produce important class of antibiotic, anti-cancer drugs
5. Gene Variant Tied to Smokers Risk of Lung Cancer
6. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
7. Holiday Online Auction - Dedicated to Awareness of Male Breast Cancer - Hosted by John W. Nick Foundation, Inc. at MaleBreastCancer.org
8. Mutations common to cancer and developmental disorder examined in a novel disease model
9. SNPs of ABC transporter genes linked to lung cancer risk
10. Gene Boosts Drinkers Colon Cancer Risk
11. Groundbreaking, inexpensive, pocket-sized ultrasound device can help treat cancer, relieve arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... , ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning ... support for efforts to educate the local population on cancer realities while attracting donations ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed ...
(Date:8/18/2017)... The Woodlands, TX (PRWEB) , ... August 18, ... ... asset protection assistance and financial planning services to communities in east Texas, is ... the Pediatric Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... Boca Raton, Fl (PRWEB) , ... August 18, ... ... nation’s largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy ... symptoms associated with hormone imbalance and conditions of aging, such as menopause, andropause, ...
(Date:8/18/2017)... IN (PRWEB) , ... August 18, 2017 , ... Inc. ... annual list, the most prestigious ranking of the nation's fastest-growing private companies. This marks ... the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/4/2017)... Md. , Aug. 4, 2017 The ... or shortly after a physician/patient consult has long been ... and was a notable focus of the largest meeting ... is according to healthcare market research firm Kalorama Information. ... care testing (POCT) offerings or related supplies and software ...
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology: